Document:

Exhibit 10.1

 

INTELLECTUAL PROPERTY SECURITY AGREEMENT

 

This Intellectual Property
Security Agreement is entered into as of March 15, 2017, by and among OXFORD FINANCE LLC, a Delaware limited liability company
with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent
(in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defined
below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender (each a “Lender”
and collectively, the “Lenders”), and ACURA PHARMACEUTICALS, INC., a New York corporation with offices located
at 616 N. North Court, Suite 120, Palatine, Illinois and ACURA PHARMACEUTICAL TECHNOLOGIES, INC., an Indiana corporation with offices
locates at 16235 State Road 17, Culver, IN 46511 (individually and collectively, jointly and severally, “Grantor”).

 

RECITALS

 

A.           Lenders
agreed to make certain advances of money and to extend certain financial accommodations to Grantor (the “Loans”)
in the amounts and manner set forth in that certain Loan and Security Agreement by and among the Collateral Agent, Lenders and
Grantor dated as of December 27, 2013 (as the same may be, and may have been, amended, modified or supplemented from time to time,
the “Loan Agreement”; capitalized terms used herein are used as defined in the Loan Agreement). In accordance
with the terms of the Loan Agreement, Grantor is granting to Collateral Agent, for the ratable benefit of the Lenders, a security
interest in certain Copyrights, Trademarks, Patents, and Mask Works (as each term is described below) to secure the obligations
of Grantor under the Loan Agreement.

 

B.           Grantor
has already granted to Collateral Agent, for the ratable benefit of the Lenders, a security interest in all of Grantor’s
right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral (other than
the Intellectual Property Collateral (as defined herein below)).

 

NOW, THEREFORE, for
good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security
for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants,
covenants and agrees as follows:

 

AGREEMENT

 

To secure its obligations
under the Loan Agreement, effective as of the date hereof, Grantor hereby grants and pledges to Collateral Agent, for the ratable
benefit of the Lenders, a security interest in all of Grantor’s right, title and interest in, to and under its intellectual
property (all of which shall collectively be called the “Intellectual Property Collateral”), including, without
limitation, the following:

 

(a)          Any
and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative
work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing,
created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the
“Copyrights”);

 

(b)          Any
and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or
hereafter existing, created, acquired or held;

 

*****Confidential treatment requested pursuant to a request
for confidential treatment filed with the Securities and Exchange Commission; omitted portions have been separately filed with
the Commission.

 

     

     

    

 

(c)          Any
and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

 

(d)          All
patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals,
reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set
forth on Exhibit B attached hereto (collectively, the “Patents”);

 

(e)          Any
trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections,
and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation
those set forth on Exhibit C attached hereto (collectively, the “Trademarks”);

 

(f)          All
mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without
limitation those set forth on Exhibit D attached hereto (collectively, the “Mask Works”);

 

(g)          Any
and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right,
but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified
above;

 

(h)          All
licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising
from such use to the extent permitted by such license or rights;

 

(i)          All
amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

 

(j)          All
proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty
payable in respect of any of the foregoing.

 

Grantor hereby represents
and warrants that the Copyrights set forth on Exhibit A, the Patents set forth on Exhibit B and the Trademarks set
forth on Exhibit C include all Copyrights, Patents and Trademarks of Grantor and its Subsidiaries that are either registered,
or for which applications for registration or grant, as applicable, are pending, on the date hereof. Grantor hereby covenants to
provide prompt notice of (A) any material change in the composition of the Intellectual Property, and (B) any new the Copyrights,
Trademarks, Patents, or Mask Works of Grantor or any of its Subsidiaries that are either registered or for which an application
for registration or grant is filed.

 

This security interest
is granted in conjunction with the security interest granted to Collateral Agent, for the ratable benefit of the Lenders under
the Loan Agreement, and shall become effective upon the date hereof. The rights and remedies of Collateral Agent with respect to
the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and
those which are now or hereafter available to Collateral Agent as a matter of law or equity. Each right, power and remedy of Collateral
Agent provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity
shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise
by Collateral Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement,
the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the
simultaneous or later exercise by any person, including Collateral Agent, of any or all other rights, powers or remedies.

 

*****Confidential treatment requested pursuant to a request
for confidential treatment filed with the Securities and Exchange Commission; omitted portions have been separately filed with
the Commission.

 

    	 	2	 

     

    

 

Notwithstanding the
foregoing, the Liens granted by this Intellectual Property Security Agreement are subject to any and all existing licenses, rights
and remedies granted by Grantor on or prior to the date hereof in accordance with the provisions of the Loan Agreement, including
those set forth in Exhibit E, with respect to the Intellectual Property Collateral. Any Intellectual Property Collateral
Transferred in accordance with the provisions of the Loan Agreement shall be deemed to have been Transferred free of Collateral
Agent’s Lien (upon consummation of the applicable Transfer in accordance with the terms of the applicable agreement(s) between
the Grantor and the party(ies) to which such Transfer is made); provided, however, the proceeds of such Intellectual Property Collateral
shall be, and for all purposes shall be deemed to be, automatically included in the Collateral and subject to the Lien and first
priority perfected security interest of Collateral Agent.

 

[Signature page follows.]

 

*****Confidential treatment requested pursuant to a request
for confidential treatment filed with the Securities and Exchange Commission; omitted portions have been separately filed with
the Commission.

 

    	 	3	 

     

    

 

IN WITNESS WHEREOF,
the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized
as of the first date written above.

 

	 	GRANTOR:
	 	 
	Address of Grantor:	ACURA PHARMACEUTICALS, INC.

 

616 N. North Court, Suite 120, Palatine,
Illinois 

	Attn: Chief Financial Officer	 	By:	/s/ Robert B. Jones
	 	 	 	 
	 	 	Title:	President & CEO

 

	 	GRANTOR:
	 	 
	Address of Grantor:	ACURA PHARMACEUTICAL TECHNOLOGIES, INC.

 

16235 State Road 17, Culver, IN 46511 

	Attn: Chief Financial Officer	 	By:	/s/ Robert B. Jones
	 	 	 	 
	 	 	Title:	President

 

	 	LENDER AND COLLATERAL AGENT:
	 	 
	Address of Lender:	OXFORD FINANCE LLC, AS COLLATERAL AGENT AND AS LENDER

 

	133 North Fairfax Street	 	By:	/s/ Mark Davis
	Alexandria, Virginia 22314	 	 	 
	Attn: Legal Department	 	Title:	Vice President – Finance, Secretary & Treasurer

 

*****Confidential treatment requested pursuant to a request
for confidential treatment filed with the Securities and Exchange Commission; omitted portions have been separately filed with
the Commission.

 

    	 	4	 

     

    

 

EXHIBIT A

 

Copyrights

  

	Description	 	
        Registration/

        Application

        Number
	 	
        Registration/

        Application

        Date

	 	 	 	 	 
	None	 	 	 	 

 

*****Confidential treatment requested pursuant to a request
for confidential treatment filed with the Securities and Exchange Commission; omitted portions have been separately filed with
the Commission.

 

    	 	5	 

     

    

 

EXHIBIT B

 

Patents

  

	Description	 	
        Registration/

        Application

        Number
	 	
        Registration/

        Application

        Date

	Methods and compositions for deterring abuse of opioid containing dosage forms	 	
        US 7,201,920

        US 7,476,402

        US 7,510,726

        US 7,981,439

        US 8,409,616

        US 8,822,489

        US 8,637,540

        US 9,492,443

        AU 2004294953

        AU 2010200979

        CA 2,547,334

        IL 175863

        IL 221018

        

        

        [*****]

        AU 2010200979

        AU 2013206525

        EP 04812083.6

        EP 11158284.7

        HK 12106471.1
	 	
        4/10/2007

        1/13/2009

        3/31/2009

        7/19/2011

        4/2/2013

        7/24/2014

        1/28/2014

        11/15/2016

        4/1/2010

        11/23/2004

        8/10/2010

        11/23/2004

        11/23/2004

        

        

        [******]

        3/15/2010

        11/23/2004

        11/23/2004

        11/23/2011

        11/23/2004

	Process to manufacture oxycodone	 	US 6,864,370	 	3/8/2005
	Process for manufacturing thebaine	 	US 6,790,959	 	9/14/2004
	Process for manufacturing codeine	 	US 6,972,332	 	12/6/2005
	Process for manufacturing codeine	 	US 6,949,645	 	9/27/2005
	Process for preparing dihydrocodeine from codeine	 	US 6,887,999	 	5/3/2005
	Preparation of opioid analgesics by a one-pot process	 	US 6,946,556	 	9/20/2005
	Preparation of oxycodone	 	US 7,071,336	 	7/4/2006
	Preparation of a 4,5-epoxymorphinan	 	US 7,348,430	 	3/25/2008
	Methods and compositions for deterring abuse	 	
        US 8,901,113

        AU 2010300641

        CA 2,775,890

        EP 2,488,029

        HK 13102020.5

        IL 218533

        

        

        US 14/552,067

        [*****]

        CA 2,775,890

        AU 2016204065

        EP 16161681.8

        HK 13102020.5

        IL 245734
	 	
        12/2/[2014]

        6/3/2016

        6/21/2016

        3/23/2016

        10/14/2016

        9/29/2016

        

        

        11/24/2014

        [******]

        9/29/2010

        9/29/2010

        9/29/2010

        9/29/2010

        9/29/2010

	Methods and compositions for self-regulated release of active pharmaceutical ingredient	 	
        US 9,101,636

        US 9,320,796

        CA 2,892,908

        JP 5,922,851

        

        

        [*****]

        WO PCT/US13/72249

        RU 2015124694
	 	8/11/2015

4/26/2016

4/12/2016

4/22/2016

[*****]

11/27/2013

6/23/2015
	Methods and Compositions for Deterring Abuse	 	US 14/322,596

CA 2,916,973

AU 2014284333

EP 14820721.0

IL 242880

CH 201480037082.5

NZ 716482	 	7/2/2014

7/2/2014

7/2/2014

7/2/2014

7/2/2014

7/2/2014

7/2/2014
	Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse	 	US 14/734,364

CA 2,951,563

AU 2015274936

EP 15807096.1

CH 201580030318.7	 	6/9/2015

6/9/2015

6/9/2015

6/9/2015

6/9/2015
	*****	 	[*****]	 	[*****]
	*****	 	[*****]	 	[*****]
	Pharmaceutical Compositions for Deterring Misuse, Abuse, and Diversion	 	WO PCT/US2010/061331	 	12/20/2010

 

*****Confidential treatment requested pursuant to a request
for confidential treatment filed with the Securities and Exchange Commission; omitted portions have been separately filed with
the Commission.

 

    	 	6	 

     

    

 

EXHIBIT C

 

Trademarks

  

	Description	 	
        Registration/

        Application

        Number
	 	
        Registration/

        Application

        Date

	 	 	 	 	 
	US- ACURA PHARMACEUTICALS	 	3114970	 	7/11/2006
	 	 	 	 	 
	US- OXAYDO	 	4847742	 	11/3/2015
	 	 	 	 	 
	US- NEXAFED	 	4151083	 	4/24/2012
	 	 	 	 	 
	US- IMPEDE	 	4289295	 	2/12/2013
	 	 	 	 	 
	US- AVERSION	 	3059542	 	2/14/2006
	 	 	 	 	 
	MEX- ACURACET	 	1087322	 	2/26/2009
	 	 	 	 	 
	MEX- IMPEDE	 	1130279	 	11/13/2009
	 	 	 	 	 
	MEX- ACUROX	 	1070309	 	11/4/2008
	 	 	 	 	 
	MEX- AVERSION	 	1182320

1087323	 	9/30/2010

2/26/2009
	 	 	 	 	 
	MEX- VYCAVERT	 	1109785	 	7/9/2009
	 	 	 	 	 
	CAN- OXAYDO	 	1724857	 	5/23/2016
	 	 	 	 	 
	CAN- AVERSION	 	832700	 	9/25/2012
	 	 	 	 	 
	CAN- ACUROX	 	757997	 	2/17/2010
	 	 	 	 	 
	CAN- VYCAVERT	 	825294	 	6/1/2012
	 	 	 	 	 
	EU- OXAYDO	 	13955935	 	8/19/2015

 

*****Confidential treatment requested pursuant to a request
for confidential treatment filed with the Securities and Exchange Commission; omitted portions have been separately filed with
the Commission.

 

    	 	7	 

     

    

 

EXHIBIT D

 

Mask Works

  

	Description	 	
        Registration/

        Application

        Number
	 	
        Registration/

        Application

        Date

	 	 	 	 	 
	None	 	 	 	 

 

*****Confidential treatment requested pursuant to a request
for confidential treatment filed with the Securities and Exchange Commission; omitted portions have been separately filed with
the Commission.

 

    	 	8	 

     

    

 

EXHIBIT E

 

Agreements potentially transferring Intellectual
Property Collateral

 

	1.	License, Commercialization and Option Agreement dated on or about March 15, 2017 between Mainpointe Pharmaceuticals, LLC and Acura Pharmaceuticals, Inc. (“Acura”).
	 	 
	2.	Collaboration and License Agreement entered into as of January 7, 2015 between Acura, Egalet US, Inc., Egalet Limited and with respect to Section 17.21, Egalet Corporation.
	 	 
	3.	License and Development Agreement dated as of June 5, 2015 between the Registrant and Bayer HealthCare LLC.
	 	 
	4.	License Agreement dated as of October 13, 2016 between Acura and Kempharm Inc.
	 	 
	5.	License and Settlement Agreement dated September 27, 2013 between Acura and Impax Laboratories, Inc.
	 	 
	6.	License Agreement dated September 27, 2013 between Acura and Par Pharmaceutical, Inc. 
	 	 
	7.	License and Settlement Agreement dated May 20, 2014 between Acura and Sandoz, Inc.
	 	 
	8.	Settlement and Patent license Agreement between Highland Pharmaceutical LLC and Acura dated as August 1, 2014

 

*****Confidential treatment requested pursuant to a request
for confidential treatment filed with the Securities and Exchange Commission; omitted portions have been separately filed with
the Commission.

 

    	 	9Exhibit 10.2

 

CONSENT AND THIRD AMENDMENT TO LOAN
AND SECURITY AGREEMENT

 

THIS CONSENT AND THIRD AMENDMENT to Loan
and Security Agreement (this “Amendment”) is entered into as of 15th March, 2017 (the “Third Amendment
Date”), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax
Street, Alexandria, Virginia 22314 (in its individual capacity, “Oxford”; and in its capacity as Collateral
Agent, “Collateral Agent”), the Lenders listed on Schedule 1.1 thereof from time to time including Oxford in
its capacity as a Lender (each a “Lender” and collectively, the “Lenders”) and ACURA PHARMACEUTICALS,
INC., a New York corporation with offices located at 616 N. North Court, Suite 120, Palatine, Illinois (“Parent”)
and ACURA PHARMACEUTICAL TECHNOLOGIES, INC., an Indiana corporation with offices locates at 16235 State Road 17, Culver, IN 46511
(“APT”, and along with Parent, individually and collectively, jointly and severally, “Borrower”).

 

WHEREAS, Collateral Agent, Borrower and
Lenders party thereto from time to time have entered into that certain Loan and Security Agreement, dated as of December 27, 2013
(as amended, supplemented or otherwise modified from time to time, the “Loan Agreement”) pursuant to which Lenders
have provided to Borrower certain loans in accordance with the terms and conditions thereof;

 

WHEREAS, Borrower anticipates entering into
a License, Commercialization and Option Agreement on or about March 15th, 2017 with MainPointe Pharmaceuticals, LLC, (“MainPointe”),
in the form provided to Collateral Agent prior to the execution hereof (the “License Agreement”);

 

WHEREAS, Loan Agreement requires Borrower
to obtain the consent of Required Lenders prior to granting certain licenses and consummating the Transfers contemplated in the
License Agreement;

 

WHEREAS, Borrower has requested that Collateral
Agent and Lenders consent to grant of certain licenses and Transfers by Borrower to MainPointe, pursuant to the License Agreement,
as described herein below; and

 

WHEREAS, in connection with and in consideration
for providing the aforementioned consent, Borrower, Lenders and Collateral Agent desire to amend certain provisions of the Loan
Agreement as provided herein and subject to the terms and conditions set forth herein.

 

NOW, THEREFORE, in consideration of the
promises, covenants and agreements contained herein, and other good and valuable consideration, the receipt and adequacy of which
are hereby acknowledged, Borrower, Lenders and Collateral Agent hereby agree as follows:

 

		1.	Capitalized terms used herein but not otherwise defined shall have the respective meanings given to them in the Loan Agreement.

 

		2.	Subject to the terms and conditions hereof, the Collateral Agent and the Required Lenders hereby consent to the Borrower’s
entry into the License Agreement in the form, and only in the form, provided to Collateral Agent prior to the execution hereof,
and consummation of the transactions contemplated therein; provided, however, Borrower may enter into and deliver any amendment
to the License Agreement and consummate the transactions as contemplated by the License Agreement after giving effect to such amendment
if, and only if, such amendments to the terms of the License Agreement: (i) would not require the consent of the Required Lenders
under Section 7 of the Loan Agreement, (ii) are not be adverse to the interests of Borrower, (iii) do not reduce the amount or
change the form of consideration due to Borrower under the License Agreement and (iv) do not postpone any payment due to Borrower
under the License Agreement. Concurrently with the execution of the Mainpointe Agreement, Collateral Agent shall have been deemed
to release its Lien (granted to it under the Loan Agreement) only on the Collateral described on Exhibit C (“Described
Collateral”); provided, however, all proceeds of the Described Collateral are and shall be included in the Collateral
in which Collateral Agent has a continuing Lien and perfected security interest under the Loan Agreement and nothing herein shall
be deemed to be a release of Collateral Agent’s Lien in the proceeds of the Described Collateral or any other Collateral.

 

*****Confidential treatment requested
pursuant to a request for confidential treatment filed with the Securities and Exchange Commission; omitted portions have been
separately filed with the Commission.

 

    	 	 	 

     

    

 

		3.	Borrower hereby reaffirms the security interest granted by Borrower previously in Section 4.1 of the Agreement with respect
to the Collateral (as defined herein) and hereby grants Collateral Agent, for the ratable benefit of the Lenders, to secure the
payment and performance in full of all of the Obligations, a continuing security interest in, and pledges to Collateral Agent,
for the ratable benefit of the Lenders, such part of the Collateral that was not pledged previously or in which security interest
was not granted prior to the Third Amendment Date, wherever located, whether now owned or hereafter acquired or arising, and all
proceeds and products thereof. Furthermore, Borrower hereby authorizes Collateral Agent to file financing statements or take any
other action required to perfect Collateral Agent’s security interests in the Collateral, without notice to Borrower, with
all appropriate jurisdictions to perfect or protect Collateral Agent’s interest or rights under the Loan Documents, including
a notice that any disposition of the Collateral, except to the extent permitted by the terms of this Agreement, by Borrower, or
any other Person, shall be deemed to violate the rights of Collateral Agent under the Code.

 

		4.	Section 5.2(d) of the Loan Agreement is hereby amended and restated as follows:

 

(d)          Borrower and each of its Subsidiaries is the
sole owner of the Intellectual Property each respectively purports to own, free and clear of all Liens other than Permitted Liens.
(i) No part of Borrower’s or its Subsidiaries’ Intellectual Property has been judged invalid or unenforceable, in whole
or in part, and to the best of Borrower’s knowledge, each of Borrower’s and its Subsidiaries’ Copyrights, Trademarks
and issued Patents are valid and enforceable and, and (ii) to the best of Borrower’s knowledge, no claim has been made that
any part of the Intellectual Property or any practice by Borrower or its Subsidiaries violates the rights of any third party
except to the extent such claim could not reasonably be expected to have a Material Adverse Change. Except as noted on the
Perfection Certificates, neither Borrower nor any of its Subsidiaries is a party to, nor is bound by, any material license
or other material agreement with respect to which Borrower or such Subsidiary is the licensee that (i) prohibits or otherwise restricts
Borrower or its Subsidiaries from granting a security interest in Borrower’s or such Subsidiaries’ interest in such
material license or material agreement or any other property, or (ii) for which a default under or termination of could interfere
with Collateral Agent’s or any Lender’s right to sell any Collateral. Borrower shall provide written notice to Collateral
Agent and each Lender within ten (10) days of Borrower or any of its Subsidiaries entering into or becoming bound by any license
or agreement with respect to which Borrower or any Subsidiary is the licensee (other than over the counter software that is commercially
available to the public).

 

		5.	Section 6.2(a)(ii) of the Loan Agreement is hereby amended and restated in its entirety as follows:

 

(ii)          as soon as available, but no later than one
hundred twenty (120) days after the last day of Borrower’s fiscal year or within five (5) days of filing with the SEC, audited
consolidated financial statements prepared under GAAP, consistently applied, together with an unqualified opinion (provided, however,
that for the fiscal year 2016, such opinion may be qualified strictly with respect to Borrower and its Subsidiary as a going concern
and unqualified otherwise) on the financial statements from an independent certified public accounting firm acceptable to Collateral
Agent in its reasonable discretion;

 

		6.	Section 6.2(a)(vii) of the Loan Agreement is hereby amended and restated in its entirety as follows:

 

(vii)          prompt notice of (A) any material change
in the composition of the Intellectual Property, (B) the registration of any copyright, including any subsequent ownership right
of Borrower or any of its Subsidiaries in or to any copyright, patent or trademark, including a copy of any such registration,
and (C) any event that could reasonably be expected to materially and adversely affect the value of the Intellectual Property;

 

*****Confidential treatment requested
pursuant to a request for confidential treatment filed with the Securities and Exchange Commission; omitted portions have been
separately filed with the Commission.

 

    	 	2	 

     

    

 

		7.	Section 6.7 of the Loan Agreement is hereby amended and restated in its entirety as follows:

 

Protection of Intellectual Property Rights.
Borrower and each of its Subsidiaries shall: (a) use commercially reasonable efforts to protect, defend and maintain the validity
and enforceability of its Intellectual Property that is material to Borrower’s business; (b) promptly advise Collateral Agent
in writing of material infringement by a third party of its Intellectual Property; and (c) not allow any Intellectual Property
material to Borrower’s business to be abandoned, forfeited or dedicated to the public without Collateral Agent’s prior
written consent. If Borrower or any of its Subsidiaries (i) obtains any patent, registered trademark or servicemark, registered
copyright, registered mask work, or any pending application for any of the foregoing, whether as owner, licensee or otherwise,
or (ii) applies for any patent or the registration of any trademark or servicemark, then Borrower or such Subsidiary shall substantially
contemporaneously provide written notice thereof to Collateral Agent and each Lender and shall execute such intellectual property
security agreements and other documents and take such other actions as Collateral Agent shall reasonably request in its good faith
business judgment to perfect and maintain a first priority perfected security interest in favor of Collateral Agent, for the ratable
benefit of the Lenders, in such property. If Borrower or any of its Subsidiaries decides to register any copyrights or mask works
in the United States Copyright Office, Borrower or such Subsidiary shall: (x) provide Collateral Agent and each Lender with at
least fifteen (15) days prior written notice of Borrower’s or such Subsidiary’s intent to register such copyrights
or mask works together with a copy of the application it intends to file with the United States Copyright Office (excluding exhibits
thereto); (y) execute an intellectual property security agreement and such other documents and take such other actions as Collateral
Agent may reasonably request in its good faith business judgment to perfect and maintain a first priority perfected security interest
in favor of Collateral Agent, for the ratable benefit of the Lenders, in the copyrights or mask works intended to be registered
with the United States Copyright Office; and (z) record such intellectual property security agreement with the United States Copyright
Office contemporaneously with filing the copyright or mask work application(s) with the United States Copyright Office. Borrower
or such Subsidiary shall promptly provide to Collateral Agent and each Lender with evidence of the recording of the intellectual
property security agreement necessary for Collateral Agent to perfect and maintain a first priority perfected security interest
in such property.

 

		8.	Section 13.1 of the Loan Agreement is hereby amended by amending and restating the following definition therein as follows:

 

		9.	“Loan Documents” are, collectively, this Agreement, the Warrants, the Perfection Certificates, each Compliance
Certificate, each Disbursement Letter, Mortgage, the Post Closing Letter and any subordination agreements, any note, or notes or
guaranties executed by Borrower or any other Person, and any other present or future agreement entered into by Borrower, any Guarantor
or any other Person for the benefit of the Lenders and Collateral Agent in connection with this Agreement; all as amended, restated,
or otherwise modified.

 

		10.	Section 13.1 of the Loan Agreement is hereby further amended by adding the following definitions thereto in alphabetical order:

 

“Third Amendment Date” is March
15th, 2017.

 

“IP Agreement” is that certain
Intellectual Property Security Agreement entered into by and between Borrower and Collateral Agent dated as of the Third Amendment
Date, as such may be amended from time to time.

 

		11.	Exhibit A to the Loan Agreement is hereby amended and restated in its entirety as set forth on Exhibit A hereto.

 

*****Confidential treatment requested
pursuant to a request for confidential treatment filed with the Securities and Exchange Commission; omitted portions have been
separately filed with the Commission.

 

    	 	3	 

     

    

 

		12.	Borrower hereby represents and warrants that a complete and accurate list of its Copyright registrations, Patents, applications
to register and registrations of Trademarks, as of the Third Amendment Date is attached hereto as Exhibit B.

 

		13.	Borrower hereby authorizes Collateral Agent to file financing statements, amendments to financing statements or take any other
action required to perfect Collateral Agent’s security interests in the Collateral (as such term has been amended pursuant
to this Amendment) , without notice to Borrower, with all appropriate jurisdictions to perfect or protect Collateral Agent’s
interest or rights under the Loan Documents, including a notice that any disposition of the Collateral, except to the extent permitted
by the terms of this Agreement, by Borrower, or any other Person, shall be deemed to violate the rights of Collateral Agent under
the Code.

 

		14.	Limitation of Amendment.

 

		a.	The amendments and the consent set forth in Sections 2 through 13 above are effective for the purposes set forth herein and
shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any
other term or condition of any Loan Document, or (b) otherwise prejudice any right, remedy or obligation which Lenders or Borrower
may now have or may have in the future under or in connection with any Loan Document, as amended hereby.

 

		b.	This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations,
warranties, covenants and agreements set forth in the Loan Documents, except as herein amended, are hereby ratified and confirmed
and shall remain in full force and effect.

 

		15.	To induce Collateral Agent and Lenders to enter into this Amendment, Borrower hereby represents and warrants to Collateral
Agent and Lenders as follows:

 

		a.	Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are
true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties
relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default has occurred and
is continuing;

 

		b.	Borrower has the power and due authority to execute and deliver this Amendment and to perform its obligations under the Loan
Agreement, as amended by this Amendment;

 

		c.	The organizational documents of Borrower delivered to Collateral Agent on the Effective Date, and updated pursuant to subsequent
deliveries by the Borrower to the Collateral Agent, remain true, accurate and complete and have not been amended, supplemented
or restated and are and continue to be in full force and effect;

 

		d.	The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan
Agreement, as amended by this Amendment, do not and will not contravene (i) any law or regulation binding on or affecting Borrower,
(ii) any contractual restriction with a Person binding on Borrower, (iii) any order, judgment or decree of any court or other governmental
or public body or authority, or subdivision thereof, binding on Borrower, or (iv) the organizational documents of Borrower;

 

*****Confidential treatment requested
pursuant to a request for confidential treatment filed with the Securities and Exchange Commission; omitted portions have been
separately filed with the Commission.

 

    	 	4	 

     

    

 

		e.	The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan
Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of,
or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof,
binding on Borrower, except as already has been obtained or made; and

 

		f.	This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against
Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization,
liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors’
rights.

 

		16.	Collateral Agent represents and warrants to Borrower that all Required Lenders have executed this Amendment.

 

		17.	Except as expressly set forth herein, the Loan Agreement shall continue in full force and effect without alteration or amendment.
This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations
or agreements.

 

		18.	This Amendment shall be deemed effective as of the Amendment Date upon (a) the due execution and delivery to Collateral Agent
of this Amendment by each party hereto, (b) the due execution and delivery to Collateral Agent of the IP Agreement by each party
thereto, (c) Collateral Agent’s receipt of the fully executed License Agreement and (d) Borrower’s payment of all Lenders’
Expenses incurred through the date hereof (not to exceed $7,500.00), which may be debited from any of Borrower’s accounts
with Lenders.

 

		19.	This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which,
taken together, shall constitute one and the same instrument.

 

		20.	This Amendment and the rights and obligations of the parties hereto shall be governed by and construed in accordance with the
laws of the State of New York.

 

[Balance of Page Intentionally Left
Blank]

 

*****Confidential treatment requested
pursuant to a request for confidential treatment filed with the Securities and Exchange Commission; omitted portions have been
separately filed with the Commission.

 

    	 	5	 

     

    

 

IN WITNESS WHEREOF, the parties hereto
have caused this Consent and Third Amendment to Loan and Security Agreement to be executed as of the Third Amendment Date.

 

	BORROWER:	 	 
	 	 	 
	ACURA PHARMACEUTICALS, INC.	 	 
	 	 	 
	By 	/s/ Robert B. Jones	 	 
	Name:  Robert B. Jones	 	 
	Title:   President and CEO	 	 
	 	 	 
	BORROWER:	 	 
	 	 	 
	ACURA PHARMACEUTICAL TECHNOLOGIES, INC.	 	 
	 	 	 
	By 	 /s/ Robert B. Jones	 	 
	Name: Robert B. Jones	 	 
	Title:   President	 	 

 

	COLLATERAL AGENT AND LENDER:	 	 
	 	 	 
	OXFORD FINANCE LLC	 	 
	 	 	 
	By 	/s/ Mark Davis	 	 
	Name:	Mark Davis	 	 
	Title:	/s/ Vice President – Finance, Secretary & Treasurer	 	 

 

*****Confidential treatment requested
pursuant to a request for confidential treatment filed with the Securities and Exchange Commission; omitted portions have been
separately filed with the Commission.

 

    	 	 	 

     

    

 

EXHIBIT A

 

Description
of Collateral

 

The Collateral consists of all of Borrower’s
right, title and interest in and to the following personal property:

 

All goods, Accounts (including health-care
receivables), Equipment, Inventory, contract rights, rights to payment of money, leases, license agreements, franchise agreements,
General Intangibles (including Intellectual Property), commercial tort claims, documents, instruments (including any promissory
notes), chattel paper (whether tangible or electronic), cash, deposit accounts and other Collateral Accounts, all certificates
of deposit, fixtures, letters of credit rights (whether or not the letter of credit is evidenced by a writing), securities, and
all other investment property, supporting obligations, and financial assets, whether now owned or hereafter acquired, wherever
located; and

 

All Borrower’s Books relating to the
foregoing, and any and all claims, rights and interests in any of the above and all substitutions for, additions, attachments,
accessories, accessions and improvements to and replacements, products, proceeds and insurance proceeds of any or all of the foregoing.

 

Notwithstanding the foregoing, the Collateral
does not include any license or contract, in each case if the granting of a Lien in such license or contract is prohibited by or
would constitute a default under the agreement governing such license or contract (but (A) only to the extent such prohibition
is enforceable under applicable law and (B) other than to the extent that any such term would be rendered ineffective pursuant
to Sections 9-406, 9-408 or 9-409 (or any other Section) of Division 9 of the Code); provided that upon the termination, lapsing
or expiration of any such prohibition, such license or contract, as applicable, shall automatically be subject to the security
interest granted in favor of Collateral Agent hereunder and become part of the “Collateral.”

 

Pursuant to the terms of a certain negative
pledge arrangement with Collateral Agent and the Lenders, Borrower has agreed not to encumber any of its Intellectual Property
(excluding Permitted Licenses).

 

*****Confidential treatment requested
pursuant to a request for confidential treatment filed with the Securities and Exchange Commission; omitted portions have been
separately filed with the Commission.

 

    	 	 	 

     

    

 

EXHIBIT B

 

Intellectual Property

 

Registered Copyrights

 

None

 

*****Confidential treatment requested
pursuant to a request for confidential treatment filed with the Securities and Exchange Commission; omitted portions have been
separately filed with the Commission.

 

    	 	 	 

     

    

 

Patents

  

	Description	 	
        Registration/

        Application

        Number
	 	
        Registration/

        Application

        Date

	Methods and compositions for deterring abuse of opioid containing dosage forms	 	US 7,201,920

US 7,476,402

US 7,510,726

US 7,981,439

US 8,409,616

US 8,822,489

US 8,637,540

US 9,492,443

AU 2004294953

AU 2010200979

CA 2,547,334

IL 175863

IL 221018

[*****]

AU 2010200979

AU 2013206525

EP 04812083.6

EP 11158284.7

HK 12106471.1	 	4/10/2007

1/13/2009

3/31/2009

7/19/2011

4/2/2013

7/24/2014

1/28/2014

11/15/2016

4/1/2010

11/23/2004

8/10/2010

11/23/2004

11/23/2004

[*****]

3/15/2010

11/23/2004

11/23/2004

11/23/2011

11/23/2004
	Process to manufacture oxycodone	 	US 6,864,370	 	3/8/2005
	Process for manufacturing thebaine	 	US 6,790,959	 	9/14/2004
	Process for manufacturing codeine	 	US 6,972,332	 	12/6/2005
	Process for manufacturing codeine	 	US 6,949,645	 	9/27/2005
	Process for preparing dihydrocodeine from codeine	 	US 6,887,999	 	5/3/2005
	Preparation of opioid analgesics by a one-pot process	 	US 6,946,556	 	9/20/2005
	Preparation of oxycodone	 	US 7,071,336	 	7/4/2006
	Preparation of a 4,5-epoxymorphinan	 	US 7,348,430	 	3/25/2008
	Methods and compositions for deterring abuse	 	US 8,901,113

AU 2010300641

CA 2,775,890

EP 2,488,029

HK 13102020.5

IL 218533

US 14/552,067

[*****]

CA 2,775,890

AU 2016204065

EP 16161681.8

HK 13102020.5

IL 245734	 	12/2/[2014]

6/3/2016

6/21/2016

3/23/2016

10/14/2016

9/29/2016

11/24/2014

[*****]

9/29/2010

9/29/2010

9/29/2010

9/29/2010

9/29/2010
	Methods and compositions for self-regulated release of active pharmaceutical ingredient	 	US 9,101,636

US 9,320,796

CA 2,892,908

JP 5,922,851

[*****]

WO PCT/US13/72249

RU 2015124694	 	8/11/2015

4/26/2016

4/12/2016

4/22/2016

[*****]

11/27/2013

6/23/2015
	Methods and Compositions for Deterring Abuse	 	US 14/322,596

CA 2,916,973

AU 2014284333

EP 14820721.0

IL 242880

CH 201480037082.5

NZ 716482	 	7/2/2014

7/2/2014

7/2/2014

7/2/2014

7/2/2014

7/2/2014

7/2/2014
	Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse	 	US 14/734,364

CA 2,951,563

AU 2015274936

EP 15807096.1

CH 201580030318.7	 	6/9/2015

6/9/2015

6/9/2015

6/9/2015

6/9/2015
	Methods and compositions for self-regulated release of active pharmaceutical	 	[*****]	 	[*****]
	Methods and compositions of self-regulating the conversion of pro-drugs to active pharmaceutical ingredients22	 	[*****]	 	[*****]
	Pharmaceutical Compositions for Deterring Misuse, Abuse, and Diversion	 	WO PCT/US2010/061331	 	12/20/2010

 

*****Confidential treatment requested
pursuant to a request for confidential treatment filed with the Securities and Exchange Commission; omitted portions have been
separately filed with the Commission.

 

    	 	 	 

     

    

 

Trademark Registrations and Applications

  

	Description	 	
        Registration/

        Application

        Number
	 	
        Registration/

        Application

        Date

	 	 	 	 	 
	US- ACURA PHARMACEUTICALS	 	3114970	 	7/11/2006
	 	 	 	 	 
	US- OXAYDO	 	4847742	 	11/3/2015
	 	 	 	 	 
	US- NEXAFED	 	4151083	 	4/24/2012
	 	 	 	 	 
	US- IMPEDE	 	4289295	 	2/12/2013
	 	 	 	 	 
	US- AVERSION	 	3059542	 	2/14/2006
	 	 	 	 	 
	MEX- ACURACET	 	1087322	 	2/26/2009
	 	 	 	 	 
	MEX- IMPEDE	 	1130279	 	11/13/2009
	 	 	 	 	 
	MEX- ACUROX	 	1070309	 	11/4/2008
	 	 	 	 	 
	MEX- AVERSION	 	1182320

1087323	 	9/30/2010

2/26/2009
	 	 	 	 	 
	MEX- VYCAVERT	 	1109785	 	7/9/2009
	 	 	 	 	 
	CAN- OXAYDO	 	1724857	 	5/23/2016
	 	 	 	 	 
	CAN- AVERSION	 	832700	 	9/25/2012
	 	 	 	 	 
	CAN- ACUROX	 	757997	 	2/17/2010
	 	 	 	 	 
	CAN- VYCAVERT	 	825294	 	6/1/2012
	 	 	 	 	 
	EU- OXAYDO	 	13955935	 	8/19/2015

 

*****Confidential treatment requested
pursuant to a request for confidential treatment filed with the Securities and Exchange Commission; omitted portions have been
separately filed with the Commission.

 

    	 	 	 

     

    

 

Exhibit C

 

Schedule of Deleted Collateral

 

	Inventory
	Warehouse:	[*****]	 	 	 	 	 	 
	Item	Lot	Description	 	 	Qty	Exp Date	Alt Product	UOI	UOM
	[*****]	 	 	 	 	 	 	 	 	 

 

*****Confidential treatment requested
pursuant to a request for confidential treatment filed with the Securities and Exchange Commission; omitted portions have been
separately filed with the Commission.

 

    	 	 	 

     

    

 

Equipment

	 	 	 
	Location:	[*****]
	Item	Asset Class	Description

  

[*****]

 

*****Confidential treatment requested
pursuant to a request for confidential treatment filed with the Securities and Exchange Commission; omitted portions have been
separately filed with the Commission.

 

    	 	 	 

     

    

 

Contracts and POS

 

Contracts

 

[*****]

 

Purchase Orders

 

Purchase Order #1048 to Patheon Pharmaceuticals,
Inc. for Nexafed Sinus 30/325 mg Tablets.

 

[*****]

 

Other

 

All domain names, brochures, promotional
and printed materials, tradeshow materials (including displays), videos, advertising materials, marketing materials, package inserts
and packaging materials (in all cases, in any form or medium) if any, owned by Acura Pharmaceuticals, Inc. or Acura Pharmaceutical
Technologies, Inc. related exclusively to the commercialization of the Nexafed products.

 

*****Confidential treatment requested
pursuant to a request for confidential treatment filed with the Securities and Exchange Commission; omitted portions have been
separately filed with the Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}]]